Jaguar Health, Inc. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 3.08 million compared to USD 3.11 million a year ago. Net loss was USD 9.5 million compared to USD 9.85 million a year ago. Basic loss per share from continuing operations was USD 219.8002 compared to USD 920.1509 a year ago.
For the nine months, revenue was USD 8.28 million compared to USD 8.18 million a year ago. Net loss was USD 30.37 million compared to USD 28.57 million a year ago. Basic loss per share from continuing operations was USD 791.3508.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
